0
Multiple Sclerosis Collection
The most recent journal, In the Clinic, and Summaries for Patients articles
Therapeutics |  May/Jun 2002
Review: In relapsing-remitting multiple sclerosis, recombinant interferon reduces exacerbations in the first 2 treatment years
Jock Murray, MD
Ann Intern Med. 2002;136(3):104. doi:10.7326/ACPJC-2002-136-3-104
Book Notes |  1 October 1991
Handbook of Multiple Sclerosis
Ann Intern Med. 1991;115(7):583. doi:10.7326/0003-4819-115-7-583_3
Diagnosis and Treatment |  1 July 1986
Mitoxantrone: A New Anticancer Drug with Significant Clinical Activity
TODD D. SHENKENBERG, M.D.; DANIEL D. VON HOFF, M.D.
Ann Intern Med. 1986;105(1):67-81. doi:10.7326/0003-4819-105-1-67
In the Clinic |  1 April 2014
Multiple Sclerosis
Daniel M. Harrison, MD
Ann Intern Med. 2014;160(7):ITC4-1. doi:10.7326/0003-4819-160-7-201404010-01004
ACP Journal Club |  18 March 2014
Review: In relapsing–remitting multiple sclerosis, disease-modifying agents reduce annual relapse rates
Brian G. Weinshenker, MD, FRCP(C)
Ann Intern Med. 2014;160(6):JC5. doi:10.7326/0003-4819-160-6-201403180-02005
ACP Journal Club |  18 May 2010
Oral fingolimod was more effective than intramuscular interferon for relapsing–remitting multiple sclerosis
James Hughes, MD
Ann Intern Med. 2010;152(10):JC5-6. doi:10.7326/0003-4819-152-10-201005180-02006
ACP Journal Club |  18 May 2010
Oral fingolimod was more effective than placebo for relapsing–remitting multiple sclerosis
James Hughes, MD
Ann Intern Med. 2010;152(10):JC5-7. doi:10.7326/0003-4819-152-10-201005180-02007
Advertisement

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)